youtube_live
Q1 2026 财报 • 2 天后
查看详情chevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
US$24.77
arrow_upward
+0.32%(+0.080) 1 天
US$24.69
arrow_downward
-0.32% (-0.080)bedtime盘后交易
休市： 5月1日, GMT-4 16:00:00 · USD
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 RARE 生成关键数据洞见…
开盘价
US$24.90
最高价
US$25.12
最低价
US$24.36
市值
二四.三五亿
平均成交量
二〇四.〇〇万
成交量
一四〇.七二万
52 周最高价
US$42.37
52 周最低价
US$18.29
每股收益
-US$5.83
Beta 版
〇.二五
流通股数
九八三一.七〇万
员工人数
一三七一
新闻报道
来自全网
The Motley Fool
·
26分钟前
Amazon Just Made a Big Move. These 2 S&P 500 Stocks Are Next to Watch.
bloomingbit
·
33分钟前
NYSE Files Rule Change to Allow Trading in Tokenized Securities
MSN
·
1小时前
This natural resources ETF has silently outperformed the S&P 500 year-to-date while yielding 5%
AASTOCKS.com
·
6小时前
半导体抛售拖累标普500及纳指於中午时段下跌美股US Stocks Quote - 外围新闻内容Golbal News Content
资料
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Ultragenyx Pharmaceutical Inc简介